title: [The effect of plasma asymmetric dimethylarginine (ADMA) level and L-arginine/ADMA ratio on the development of coronary collaterals].
abstract: OBJECTIVE
  It has been shown that asymmetric dimethylarginine (ADMA), an endogenous competitive antagonist of nitric oxide (NO) synthase, inhibits angiogenesis by reducing the production and bioavailability of NO. We investigated the effect of plasma ADMA level and L-arginine/ADMA ratio on the development of coronary collateral arteries.
  
  
  METHODS
  The study consisted of 94 patients (66 males, 28 females; mean age 59+/-11 years) who underwent coronary angiography for suspected coronary artery disease and were found to have severe stenosis (>95%) in at least one major coronary artery. The patients were evaluated in two groups with poor (Rentrop score 0-1, n=44) and good (score 2-3, n=50) coronary collateral circulation according to the Rentrop collateral scoring system. Plasma levels of ADMA and L-arginine were measured by high-performance liquid chromatography.
  
  
  RESULTS
  The two groups were similar with regard to basal characteristics and cardiovascular risk factors (p>0.05) except for stable angina, which was more common in patients with Rentrop score 2-3 collateral circulation (p<0.001). Despite similar L-arginine levels (p>0.05), patients with Rentrop score 0-1 had a significantly higher ADMA level (p=0.003) and lower L-arginine/ADMA ratio (p=0.019). Multivariate logistic regression analysis showed that plasma ADMA concentration was an independent predictor of coronary collateral development (odds ratio=0.674; 95% confidence interval=0.508-0.894; p=0.006).
  
  
  CONCLUSIONS
  Elevated plasma ADMA concentrations are associated with a poorly developed coronary collateral circulation, suggesting that dysregulation of the NO synthase pathway may result in impaired collateral development.
authors.affiliation: Department of Cardiology, Türkiye Yüksek Ihtisas Heart Education and Research Hospital, Ankara, Turkey. timurselcuk@hotmail.com
authors.forename: Mehmet Timur
authors.initials: MT
authors.lastname: Selçuk
authors.forename: Hatice
authors.initials: H
authors.lastname: Selçuk
authors.forename: Ahmet
authors.initials: A
authors.lastname: Temizhan
authors.forename: Orhan
authors.initials: O
authors.lastname: Maden
authors.forename: Hakan
authors.initials: H
authors.lastname: Ulupinar
authors.forename: Erkan
authors.initials: E
authors.lastname: Baysal
authors.forename: Erdal
authors.initials: E
authors.lastname: Duru
authors.forename: Ali
authors.initials: A
authors.lastname: Saşmaz
mesh_terms: D001120:Arginine / Q000031:analogs & derivatives* / Q000097:blood*; D002851:Chromatography, High Pressure Liquid; D003097:Collateral Circulation / Q000502:physiology*; D016001:Confidence Intervals; D023921:Coronary Stenosis / Q000097:blood / Q000175:diagnosis* / Q000503:physiopathology; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D016017:Odds Ratio; D012307:Risk Factors
chemical_list: C018524:N,N-dimethylarginine; D001120:Arginine; D019001:Nitric Oxide Synthase